Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
1. Main purpose:
To evaluate the efficacy and safety of rituximab combined with tacrolimus in the
treatment of intermediate and high-risk primary membranous nephropathy
2. Secondary research purposes:
To describe the survival of patients with intermediate and high-risk primary membranous
nephropathy treated with rituximab combined with tacrolimus; To describe renal survival
in patients with intermediate and high-risk primary membranous nephropathy treated with
rituximab combined with tacrolimus;
3. Exploratory research purposes:
Feasibility of glucocorticoids-free therapy (rituximab combined with tacrolimus) in the
treatment of intermediate and high-risk primary membranous nephropathy